Aberdeen Group
VIGL

Aberdeen Group’s Vigil Neuroscience VIGL Stock Holding History

Aberdeen Group’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,724,520
Closed -$3.07M – 977
2025
Q1 		$3.07M Buy
1,724,520
+1,196,048
+226% +$2.68M 0.01% 725
2024
Q4 		$898K Buy
528,472
+293,461
+125% +$867K ﹤0.01% 831
2024
Q3 		$799K Buy
+235,011
New +$871K ﹤0.01% 824

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Aberdeen Group's VIGL Position: Q2 2025 in Review

Aberdeen Group sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 1,724,520 shares — an estimated $3.07M sold.

Aberdeen Group first reported a position in VIGL in Q3 2024 and held it in 3 quarters. The position peaked at $3.07M in Q1 2025. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • Aberdeen Group reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Aberdeen Group sold 1,724,520 Vigil Neuroscience shares in Q2 2025, an estimated $3.07M.
  • Aberdeen Group first reported a position in Vigil Neuroscience in Q3 2024 and held it in 3 quarters.
  • Aberdeen Group's Vigil Neuroscience position peaked at $3.07M in Q1 2025.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on Aberdeen Group's 13F filing for Q2 2025, filed 24 Jul 2025.